IﬂD£M5
V . . > r “’ :r‘léhis
Patient Name: h V Med Rec #: ()QWQLLYTW’ AflanMUJ; $06

. _. « ‘, I ‘, <~
3::2:::: :3 at; 6 MM Ngggq
"W (3/61/14

Report Name: ‘:

S P th Ca e — STATUS: Final
uxg e S UUID:E17EECA7-260E-4456-9432-635A9F4931AD
**SEE NOTE: Collect/Perform: TCGA-MY-AQlS-OlA-PR Redacted
Ordered By: Ordered Date: 5 H u I"

HHIHIHIIIIIIIIIllllllllllllllllllllll l
llllllllIllIHlllllllllllllllllllllllll I" ”'""”'"”

l
llllllllllllllllllllllllllllllllll||||I|lllllgllhllllhlhlllﬂlll

Department:

Physician Who Performed 9rocedure: _ ll
Requesting Physician:

Attending Fathologist 2

DIAGNOSIS :

Cervix, bigpsy:

— Fragments of invasive poorly- differentiated squamous carcinoma.
- orientation precludes measurement: cf depth of invasion.

comm: There is a copious amount of sampled tissue, alums: all of which
is composed qf

tumor. A 963 stain is strongiy positive supporting the éiagneaia.

=x==nuaa==== ======

 

n—n s :¢$

CLINICAL INFORMATXON:
Cervical cancer

GROSS DESCRIPTION :

The specimen is received fresh labeled "cervical biopsy“. It consists oE a
2 x 0.7 x 0.4 cm

irregular portion of tan rubbery tissue: one aspect demonstrates apparent
can smooth mucosa. The tissue is inked and serially sectioned. The cut:
surfaces are can and smooth. Also received are two can rubbery tissue
fragments measuring 0.5 x 0‘4 x 0.2 cm in aggregate. The specimen is
entirely eubmitted in three cassettes as follcws:

1A-1B— largest portion of tissue, sectioned

1c separately received tissue fragments

The following special studies were performed on this case and the

interpretation is incorporateci in the ciagnostic report above:

ioFZ

Patient Namdi ‘ Med Rec #:3

Requested By:
ordered By

Report Name:

** Electronic Signature **

**Electronically Signed Out by

I certify that I personally conducted the diagnostic evaluation of the
above specimen(s) and have rendered the Sinai diagnosis(es).

Note: The histology, immunochemistry and in siCu hybridization components
for this case were performed at

The Attending Facbologisc reviewed this case and made the diagnosis.
Where applicable, immunohistochemistry and in Situ hybxidizacion tests were
developed and the performance characteristics determined by the

have not been cleared or approved by the US Food and Drug Administration
ané the results should be correlated with other clinical and laboratory
data. Appropriate controls were performed for all immunohiatochemistry; in
situ hybridization and hiatochemical tests.

Prior

(as: is

Tumor Site

Initials

 

